An independent Data and Safety Monitoring Board has completed the successful review of the safety data of the Phase IIb clinical trial of TNF-Kinoid in rheumatoid arthritis (RA), according to an annual statement issued by Neovacs.

The biotech company, which focuses on an active immunotherapy technology platform with applications in autoimmune and/or inflammatory diseases, has now received a final report in with unrestricted approval of the study. The committee of four international auto-immune disease experts have confirmed the good safety profile of the Kinoid at the actual stage of the study, and made a unanimous recommendation to pursue the study without modification, stated Neovacs.

"From a clinical point of view, 2013 was an important year for Neovacs, with the launch of our phase IIb trial in RA. 2014 will also be a critical year. The RA clinical study is progressing according to schedule,” said Miguel Sieler, CEO of Neovacs. “We are also resuming preclinical studies with three other Kinoids, in order to maintain our leadership position in the development of immunotherapies for the treatment of auto-immune diseases, chronic infections and cancer. I am confident that the clinical data that we will present in 2014 will prove the efficacy of our products, and allow Neovacs to reach the next phase of its development". 

News

An independent Data and Safety Monitoring Board has completed the successful review of the safety data of the Phase IIb clinical trial of TNF-Kinoid in rheumatoid arthritis